Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms |
Target |
Mechanism CD3 modulators(T cell surface glycoprotein CD3 modulators), MUC17 inhibitors(mucin 17, cell surface associated inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Muc17 positive Stomach Cancer | Preclinical | CN | 14 Apr 2023 |